The relation between NOD2/CARD15 mutations and the prevalence and phenotypic heterogeneity of crohn's disease: Lessons from the Israeli Arab Crohn's Disease Cohort

被引:23
作者
Karban, A [1 ]
Atia, O
Leitersdorf, E
Shahbari, A
Sbeit, W
Ackerman, Z
Mualem, R
Levine, A
Nesher, S
Safadi, R
Eliakim, R
机构
[1] Rambam Med Ctr, Dept Gastroenterol, Haifa, Israel
[2] Hadassah Univ Hosp, Dept Med B, IL-91120 Jerusalem, Israel
[3] Hadassah Univ Hosp, Dept Internal Med, IL-91120 Jerusalem, Israel
[4] Hadassah Univ Hosp, Liver Unit, IL-91120 Jerusalem, Israel
[5] Cent Emek Hosp, Gastroenterol Unit, IL-18101 Afula, Israel
[6] Western Galilee Hosp, Dept Gastroenterol, Nahariyya, Israel
[7] Poriah Hosp, Gastroenterol Unit, Tveria, Israel
[8] E Wolfson Med Ctr, Pediat Gastroenterol Unit, Holon, Israel
关键词
Crohn's disease; NOD2/CARD15; genetics; Israel; Arabs;
D O I
10.1007/s10620-005-2917-x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The prevalence of Crohn's disease depends on geographic location and racial background. Arg702Trp, Gly908Arg, and Leu1007fsinsC mutations in the NOD2/CARD15 gene are associated with Crohn's disease in Caucasians. The mutation rate among Israeli Jewish patients is 27%-41%. The prevalence of Crohn's disease is much lower in the Israeli Arab compared to the Israeli Jewish population. We studied the NOD2/CARD15 mutation rate and disease phenotype (according to the Vienna classification) among the Israeli Arabs and compared them with those in an Israeli Jewish cohort. We recruited 66 Israeli Arab patients and 122 ethnically matched controls. Five patients (8.2%) and three controls (2.3%) carried one NOD2/CARD15 mutation. The phenotypic characteristics of the Arab and Jewish patients were very similar. We conclude that NOD2/CARD15 mutations do not contribute to Crohn's susceptibility in the Israeli Arab population and suggest that NOD2/CARD15 mutations have an important effect on Crohn's prevalence within a specific population but not on the phenotype.
引用
收藏
页码:1692 / 1697
页数:6
相关论文
共 48 条
[1]
Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease [J].
Abreu, MT ;
Taylor, KD ;
Lin, YC ;
Hang, T ;
Gaiennie, J ;
Landers, CJ ;
Vasiliauskas, EA ;
Kam, LY ;
Rojany, M ;
Papadakis, KA ;
Rotter, JI ;
Targan, SR ;
Yang, HY .
GASTROENTEROLOGY, 2002, 123 (03) :679-688
[2]
Clinical relevance of advances in genetics and pharmacogenetics of IBD [J].
Ahmad, T ;
Tamboli, CP ;
Jewell, D ;
Colombel, JF .
GASTROENTEROLOGY, 2004, 126 (06) :1533-1549
[3]
The molecular classification of the clinical manifestations of Crohn's disease [J].
Ahmad, T ;
Armuzzi, A ;
Bunce, M ;
Mulcahy-Hawes, K ;
Marshall, SE ;
Orchard, TR ;
Crawshaw, J ;
Large, O ;
De Silva, A ;
Cook, JT ;
Barnardo, M ;
Cullen, S ;
Welsh, KI ;
Jewell, DP .
GASTROENTEROLOGY, 2002, 122 (04) :854-866
[4]
Crohn's disease in the Hunter Valley region of Australia [J].
Anseline, PF .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1995, 65 (08) :564-569
[5]
NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? [J].
Arnott, IDR ;
Nimmo, ER ;
Drummond, HE ;
Fennell, J ;
Smith, BRK ;
MacKinlay, E ;
Morecroft, J ;
Anderson, N ;
Kelleher, D ;
O'Sullivan, M ;
McManus, R ;
Satsangi, J .
GENES AND IMMUNITY, 2004, 5 (05) :417-425
[6]
Bernstein CN, 1999, AM J EPIDEMIOL, V149, P916, DOI 10.1093/oxfordjournals.aje.a009735
[7]
The genetics of inflammatory bowel disease [J].
Bonen, DK ;
Cho, JH .
GASTROENTEROLOGY, 2003, 124 (02) :521-536
[8]
Bonen DK, 2002, GASTROENTEROLOGY, V122, pA29
[9]
CARD15/NOD2 risk alleles in the development of Crohn's disease in the Australian population [J].
Cavanaugh, JA ;
Adams, KE ;
Quak, EJ ;
Bryce, ME ;
O'Callaghan, NJ ;
Rodgers, HJ ;
Magarry, GR ;
Butler, WJ ;
Eaden, JA ;
Roberts-Thomson, IC ;
Pavli, R ;
Wilson, SR ;
Callen, DF .
ANNALS OF HUMAN GENETICS, 2003, 67 :35-41
[10]
Race and genomics [J].
Cooper, RS ;
Kaufman, JS ;
Ward, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (12) :1166-1170